2025年前三季度全球制药营收TOP10！

药融圈2025-11-17

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。2025年前三季度的财务数据陆续揭晓，全球领先制药公司的业绩表现呈现出清晰的增长图谱。从绝对营收来看，礼来在前九个月累计实现营收458.87亿美元，同比增长高达46%，毫无悬念地登上榜首。其第三季度单季176.01亿美元的收入及54%的同比增幅，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2584678176?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-17 09:48","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2584678176","market":"us","top_or_hot":-1,"title":"2025年前三季度全球制药营收TOP10！","media":"药融圈","content":"<div>\n<p>注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。2025年前三季度的财务数据陆续揭晓，全球领先制药公司的业绩表现呈现出清晰的增长图谱。从绝对营收来看，礼来在前九个月累计实现营收458.87亿美元，同比增长高达46%，毫无悬念地登上榜首。其第三季度单季176.01亿美元的收入及54%的同比增幅，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117100415a4a66bbf&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2025年前三季度全球制药营收TOP10！</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2025年前三季度全球制药营收TOP10！\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-17 09:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117100415a4a66bbf&s=b><strong>药融圈</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。2025年前三季度的财务数据陆续揭晓，全球领先制药公司的业绩表现呈现出清晰的增长图谱。从绝对营收来看，礼来在前九个月累计实现营收458.87亿美元，同比增长高达46%，毫无悬念地登上榜首。其第三季度单季176.01亿美元的收入及54%的同比增幅，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117100415a4a66bbf&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B1BXHZ80.USD","symbol_name":"Legg Mason ClearBridge - US Appreciation A Acc USD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117100415a4a66bbf&s=b","article_id":"2584678176","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117100415a4a66bbf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2584678176","pubTimestamp":1763344138,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"2025年前三季度的财务数据陆续揭晓，全球领先制药公司的业绩表现呈现出清晰的增长图谱。紧随其后的是辉瑞，前三季度营收450.22亿美元，位列第二。然而，与礼来的高增长形成对比，辉瑞的业绩出现小幅下滑，前三季度和第三季度营收分别同比下降2%和6%。阿斯利康前三季度营收432.36亿美元，同比增长11%，是前十强中增速最快的公司之一，阿斯利康在肿瘤、心血管代谢疾病领域的创新药布局成效显著。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","BK4534":"瑞士信贷持仓","IE00BKDWB100.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5H\" (SGDHDG) ACC","LU2168563687.JPY":"AZ ALLOCATION - TREND \"AAZ\" (JPYHDG) ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU2746668461.USD":"MANULIFE DYNAMIC LEADERS \"AA\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","BK4516":"特朗普概念","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","BMS":"碧美斯","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","SG9999001176.USD":"United Global Healthcare Acc USD","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","SGXZ81514606.USD":"大华环球创新基金A Acc USD","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU1548497426.USD":"安联环球人工智能AT Acc","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU2168564495.EUR":"AZ ALLOCATION - TREND \"AI\" (EUR) ACC","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU0079474960.USD":"联博美国增长基金A","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","BK4599":"减肥药","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU2168564222.USD":"AZ ALLOCATION - TREND \"AAZ\" (USDHDG) ACC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LLY":"礼来","LU2168564065.EUR":"AZ ALLOCATION - TREND \"AAZ\" (EUR) ACC"},"translate_title":"TOP10 global pharmaceutical revenue in the first three quarters of 2025!","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMS":1,"LLY":0.9},"content_text":"注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。2025年前三季度的财务数据陆续揭晓，全球领先制药公司的业绩表现呈现出清晰的增长图谱。从绝对营收来看，礼来在前九个月累计实现营收458.87亿美元，同比增长高达46%，毫无悬念地登上榜首。其第三季度单季176.01亿美元的收入及54%的同比增幅，更是彰显了其强劲的增长势头。这一表现主要得益于其在糖尿病和肥胖症领域重磅药物，如GIP/GLP-1受体激动剂的巨大市场需求，强大的创新产品管线已成为其业绩的核心引擎。紧随其后的是辉瑞，前三季度营收450.22亿美元，位列第二。然而，与礼来的高增长形成对比，辉瑞的业绩出现小幅下滑，前三季度和第三季度营收分别同比下降2%和6%。这反映出其在新冠产品需求常态化后，正处于业务周期的调整阶段，需要依靠其他创新产品和收购来填补收入缺口。排名第三至第五的强生、艾伯维和默沙东营收均超过430亿美元。这三家公司均实现了小幅正增长或持平，显示出其成熟产品组合的抗风险能力。其中，艾伯维第三季度9%的增速在该梯队中较为突出。增长亮点是排名第六的阿斯利康和第八的诺华。阿斯利康前三季度营收432.36亿美元，同比增长11%，是前十强中增速最快的公司之一，阿斯利康在肿瘤、心血管代谢疾病领域的创新药布局成效显著。诺华同样以11%的前三季度增速，实现了411.96亿美元的营收，其聚焦于核心治疗领域的战略正在收获回报。罗氏（制药业务）和赛诺菲作为欧洲药企的代表，分别以425.45亿美元和375.00亿美元的营收位列第七和第九，并分别取得了9%和9%（前三季度）的可观增长。这表明其在面对市场竞争和专利到期挑战时，通过内部研发和外部合作保持了竞争力。百时美施贵宝（BMS）则以356.92亿美元的营收排名第十，业绩微降1%。展望未来，制药行业的竞争将愈发集中于前沿科技领域，如细胞与基因治疗、神经科学、人工智能驱动的新药研发等。对于这些巨头而言，如何平衡现有产品的收入与对未来管线的巨额投资，将决定其在下一个五年排行榜上的座次。参考：药朋械友","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584678176","isCrawlerRequest":true}